Longeveron Inc. 8K

Longeveron Inc. announced Q2 2026 results and a comprehensive business update, emphasizing imminent pivotal clinical milestones for laromestrocel, XPRIZE Healthspan recognition and award funding, and a limited cash runway expected to extend into Q4 2026.

On August 12, 2026, Longeveron Inc. reported its financial results for the quarter ended June 30, 2026 and provided a broad business update, highlighting progress across its laromestrocel (Lomecel-B) clinical programs, including the upcoming September 2026 top-line readout from the Phase 2b ELPIS II trial in hypoplastic left heart syndrome (HLHS), additional supportive data in Alzheimer’s disease and aging-related frailty, and plans to initiate a Phase 2 registrational trial in pediatric dilated cardiomyopathy in 2027. The company also announced several corporate developments, including selection as a Finalist Team and Milestone 2 Awardee in the XPRIZE Healthspan competition (with a $1.0 million award), the addition of three new independent directors to its board, the grant of SME status by the European Medicines Agency, and issuance of a new patent in China covering potency assay methods for mesenchymal stem cells. Financially, Longeveron reported flat quarterly revenue of $0.3 million, a higher net loss of $6.1 million versus $5.0 million a year earlier driven mainly by increased legal and clinical trial costs, and cash and cash equivalents of $10.1 million as of June 30, 2026, which management expects to fund operations into the fourth quarter of 2026, with plans to seek additional financing and non-dilutive funding to support its operating plans.

Filing Facts

CIK

1721484

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-088365

Alert Tier

6